Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Immunotherapy Study of Evofosfamide in Combination With Ipilimumab in Patients With Advanced Solid Malignancies

X
Trial Profile

A Phase 1 Immunotherapy Study of Evofosfamide in Combination With Ipilimumab in Patients With Advanced Solid Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evofosfamide (Primary) ; Ipilimumab (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Pancreatic cancer; Prostate cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Threshold Pharmaceuticals
  • Most Recent Events

    • 16 Jun 2021 Results published in the ImmunoGenesis Media Release
    • 26 Mar 2021 Results assessing (n=21; Median age= 67 years) safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of combining evofosfamide and ipilimumab in patients with advanced solid tumors, published in the Clinical Cancer Research.
    • 13 Jun 2017 According to a Threshold Pharmaceuticals media release, first patient has been dosed in the trial at the University of Texas MD Anderson Cancer Center.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top